• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Ethical issues and risk/benefit assessment of iron chelation therapy: advances with deferiprone/deferoxamine combinations and concerns about the safety, efficacy and costs of deferasirox [Kontoghiorghes GJ, Hemoglobin 2008; 32(1-2):1-15.].

作者信息

Porter John B, Taher Ali T, Cappellini Maria D, Vichinsky Elliott P

出版信息

Hemoglobin. 2008;32(6):601-7. doi: 10.1080/03630260802342008.

DOI:10.1080/03630260802342008
PMID:19065340
Abstract
摘要

相似文献

1
Ethical issues and risk/benefit assessment of iron chelation therapy: advances with deferiprone/deferoxamine combinations and concerns about the safety, efficacy and costs of deferasirox [Kontoghiorghes GJ, Hemoglobin 2008; 32(1-2):1-15.].
Hemoglobin. 2008;32(6):601-7. doi: 10.1080/03630260802342008.
2
Ethical issues and risk/benefit assessment of iron chelation therapy: advances with deferiprone/deferoxamine combinations and concerns about the safety, efficacy and costs of deferasirox.铁螯合疗法的伦理问题及风险/效益评估：去铁酮/去铁胺联合疗法的进展以及对地拉罗司安全性、有效性和成本的担忧。
Hemoglobin. 2008;32(1-2):1-15. doi: 10.1080/03630260701726533.
3
Transparency and access to full information for the fatal or serious toxicity risks, low efficacy and high price of deferasirox, could increase the prospect of improved iron chelation therapy worldwide.对于地拉罗司的致命或严重毒性风险、低疗效和高价格，提高透明度并提供全面信息，可能会增加全球改善铁螯合治疗的前景。
Hemoglobin. 2008;32(6):608-15. doi: 10.1080/03630260802341703.
4
Introduction of higher doses of deferasirox: better efficacy but not effective iron removal from the heart and increased risks of serious toxicities.介绍更高剂量的地拉罗司：疗效更好，但不能有效去除心脏中的铁，且严重毒性风险增加。
Expert Opin Drug Saf. 2010 Jul;9(4):633-41. doi: 10.1517/14740338.2010.497138.
5
Deferasirox (Exjade): a new iron chelator.地拉罗司（恩瑞格）：一种新型铁螯合剂。
Med Lett Drugs Ther. 2006 Apr 24;48(1233):35-6.
6
Clinical monitoring and management of complications related to chelation therapy in patients with β-thalassemia.β-地中海贫血患者螯合治疗相关并发症的临床监测与管理。
Expert Rev Hematol. 2016;9(2):151-68. doi: 10.1586/17474086.2016.1126176. Epub 2015 Dec 19.
7
Update on toxicity and efficacy aspects of treatment with deferasirox and its implication on the morbidity and mortality of transfused iron loaded patients.地拉罗司治疗的毒性和疗效方面的最新进展及其对输血性铁过载患者发病率和死亡率的影响
Expert Opin Drug Saf. 2008 Nov;7(6):645-6. doi: 10.1517/14740330802137479.
8
Iron chelation therapy of transfusion-dependent β-thalassemia during pregnancy in the era of novel drugs: is deferasirox toxic?新型药物时代孕期输血依赖型β地中海贫血的铁螯合疗法：地拉罗司有毒性吗？
Int J Hematol. 2016 May;103(5):537-44. doi: 10.1007/s12185-016-1945-y. Epub 2016 Feb 9.
9
Iron chelation therapy in myelodysplastic syndromes.骨髓增生异常综合征的铁螯合疗法。
Am J Health Syst Pharm. 2010 Apr;67(7 Suppl 2):S10-4; quiz S16. doi: 10.2146/ajhp090654.
10
Incidence of deferasirox-associated renal tubular dysfunction in children and young adults with beta-thalassaemia.地拉罗司相关肾小管功能障碍在儿童和年轻成人β地中海贫血患者中的发生率。
Br J Haematol. 2014 Nov;167(3):434-6. doi: 10.1111/bjh.13002. Epub 2014 Jul 2.

引用本文的文献

1
Focus on the role of calcium signaling in ferroptosis: a potential therapeutic strategy for sepsis-induced acute lung injury.关注钙信号在铁死亡中的作用：脓毒症诱导的急性肺损伤的潜在治疗策略。
Front Med (Lausanne). 2024 Sep 17;11:1457882. doi: 10.3389/fmed.2024.1457882. eCollection 2024.
2
Targeting ferroptosis opens new avenues for the development of novel therapeutics.靶向铁死亡为新型治疗药物的开发开辟了新途径。
Signal Transduct Target Ther. 2023 Sep 21;8(1):372. doi: 10.1038/s41392-023-01606-1.
3
New developments and controversies in iron metabolism and iron chelation therapy.
铁代谢与铁螯合疗法的新进展及争议
World J Methodol. 2016 Mar 26;6(1):1-19. doi: 10.5662/wjm.v6.i1.1.
4
TLc-A, the leading nanochelating-based nanochelator, reduces iron overload in vitro and in vivo.TLc-A是领先的基于纳米螯合的纳米螯合剂，可在体外和体内减轻铁过载。
Int J Hematol. 2016 Mar;103(3):274-82. doi: 10.1007/s12185-015-1932-8. Epub 2016 Feb 1.
5
World health dilemmas: Orphan and rare diseases, orphan drugs and orphan patients.全球健康困境：孤儿病与罕见病、孤儿药与孤儿患者
World J Methodol. 2014 Sep 26;4(3):163-88. doi: 10.5662/wjm.v4.i3.163.